Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Creative Medical Technology Holdings, Inc. CELZ

Healthcare  —  Biotechnology
1.03 0.06 6.19% as of 25 Sep
Market cap
$6.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Creative Medical Technology Holdings, Inc. (CELZ) Business Profile

Updated before January 2025

Company Overview

Creative Medical Technology Holdings, Inc. (CELZ) is a biotechnology company specializing in regenerative medicine and stem cell technology. Founded in 2011, the company is headquartered in Phoenix, Arizona. CELZ focuses on developing innovative solutions for unmet medical needs, leveraging its proprietary technologies and expertise in stem cell research. The company is led by a team of experienced professionals, including Timothy Warbington, who serves as the President and CEO. Under his leadership, CELZ has made significant strides in advancing its product pipeline and expanding its market presence.

Core Business Segments

Regenerative Medicine

CELZ’s primary focus is on regenerative medicine, where it develops therapies aimed at repairing or replacing damaged tissues and organs. The company’s flagship product, CaverStem®, is a stem cell therapy designed to treat erectile dysfunction by utilizing the patient’s own stem cells to regenerate damaged tissues. Another key product is FemCelz®, which targets female sexual dysfunction and pelvic health issues.

Immunotherapy

In addition to regenerative medicine, CELZ is exploring the potential of stem cell-based immunotherapies. These therapies aim to harness the immune system to combat diseases such as cancer and autoimmune disorders. The company is actively conducting research and development in this area to expand its product offerings.

Neurology

CELZ is also working on developing treatments for neurological disorders, including stroke recovery and neurodegenerative diseases. By leveraging its proprietary stem cell technologies, the company aims to provide innovative solutions for conditions with limited treatment options.

Business Model

CELZ operates on a business model that integrates research, product development, and commercialization. The company generates revenue through the sale of its proprietary therapies and licensing agreements with other organizations. CELZ also collaborates with academic institutions and research organizations to advance its technologies and expand its product pipeline. By focusing on high-growth markets such as regenerative medicine and immunotherapy, CELZ aims to achieve sustainable revenue growth and long-term profitability.

Strategic Direction

CELZ is committed to advancing its position as a leader in regenerative medicine and stem cell technology. The company’s strategic goals include:

  • Expanding Product Portfolio: CELZ plans to develop new therapies targeting additional medical conditions, such as autoimmune diseases and chronic pain.
  • Global Market Expansion: The company aims to enter new geographic markets, including Europe and Asia, to increase its global footprint.
  • Sustainability Goals: CELZ is dedicated to adopting environmentally sustainable practices in its operations and product development processes.
  • Research and Development: CELZ continues to invest in R&D to enhance its existing products and discover new applications for its stem cell technologies.

Competitive Landscape

CELZ operates in a highly competitive market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Mesoblast Limited: A global leader in regenerative medicine, specializing in allogeneic cellular medicines.
  • Athersys, Inc.: Focused on developing therapies for neurological and inflammatory conditions.
  • Pluristem Therapeutics: Known for its placenta-based cell therapy products.
  • Organogenesis Holdings Inc.: Offers advanced wound care and surgical products.

Despite the competition, CELZ differentiates itself through its proprietary technologies and focus on niche markets such as sexual health and pelvic health.

Risk Factors

CELZ faces several risks that could impact its operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its flagship products, such as CaverStem® and FemCelz®.
  • Regulatory Challenges: The development and approval of stem cell therapies are subject to stringent regulatory requirements, which could delay product launches.
  • Supply Chain Disruptions: CELZ depends on a reliable supply chain for the production of its therapies. Any disruptions could affect its ability to meet market demand.
  • Competition: The regenerative medicine market is highly competitive, with numerous players vying for market share.

Recent Developments

CELZ has recently achieved several milestones, including:

  • FDA Clearance: The company received FDA clearance for its CaverStem® therapy, paving the way for commercialization in the U.S. market.
  • Partnerships: CELZ entered into strategic partnerships with leading research institutions to advance its product pipeline.
  • New Product Launches: The company launched FemCelz® in select markets, targeting a growing demand for female sexual health solutions.
  • Global Developments: CELZ is exploring opportunities to expand its presence in international markets, particularly in Europe and Asia.

Investment Considerations

Strengths

  • Innovative Product Portfolio: CELZ offers cutting-edge therapies that address unmet medical needs.
  • Experienced Leadership: The company is led by a team of seasoned professionals with expertise in biotechnology and regenerative medicine.
  • Growth Potential: CELZ operates in high-growth markets, such as regenerative medicine and immunotherapy.

Risks

  • Regulatory Hurdles: The approval process for stem cell therapies is complex and time-consuming.
  • Market Competition: CELZ faces competition from both established players and emerging biotech firms.
  • Financial Stability: As a relatively small company, CELZ may face challenges in securing funding for its operations and R&D activities.

Conclusion

Creative Medical Technology Holdings, Inc. is a pioneering biotechnology company with a strong focus on regenerative medicine and stem cell technology. With an innovative product portfolio and a commitment to advancing medical science, CELZ is well-positioned to capitalize on the growing demand for regenerative therapies. While the company faces challenges such as regulatory hurdles and market competition, its strategic initiatives and experienced leadership provide a solid foundation for future growth. Investors should carefully consider the company’s strengths and risks before making investment decisions.